This site is intended for U.S. Healthcare Professionals only.
For SRT-eligible patients with NYHA class II-III obstructive HCM,
CI=confidence interval; HCM=hypertrophic cardiomyopathy; LVOT=left ventricular outflow tract obstruction; NYHA=New York Heart Association; SD=standard deviation; SRT=septal reduction therapy.
While these exploratory endpoints were prespecified, they were not powered for significance.2
ADVERSE REACTIONS
Based on the safety profile from the pivotal EXPLORER-HCM trial, there were no new adverse reactions identified in VALOR-HCM.
For SRT-eligible patients with NYHA class II-III obstructive HCM,
CI=confidence interval; HCM=hypertrophic cardiomyopathy; NYHA=New York Heart Association; SRT=septal reduction therapy.
Data below showing improvement of ≥ 2 classes was exploratory in nature and not powered for significance.
ADVERSE REACTIONS
Based on the safety profile from the pivotal EXPLORER-HCM trial, there were no new adverse reactions identified in VALOR-HCM.
For SRT-eligible patients with NYHA class II-III obstructive HCM,
KCCQ-23–CSS=Kansas City Cardiomyopathy Questionnaire (23-item version)-Clinical Summary Score; LS=least squares; PL=physical limitations; SD=standard deviation; SE=standard error; TSS=total symptom score.
ADVERSE REACTIONS
Based on the safety profile from the pivotal EXPLORER-HCM trial, there were no new adverse reactions identified in VALOR-HCM.
For SRT-eligible patients with NYHA class II-III obstructive HCM,
The clinical significance of the NT-proBNP and cardiac troponin I findings is unknown
*Geometric mean ratios <1.0 represent an x-fold decrease for CAMZYOS compared with placebo.2
CI=confidence interval; GM=geometric mean; HCM=hypertrophic cardiomyopathy; NYHA=New York Heart Association; NT-proBNP=N-terminal pro B-type natriuretic peptide; SRT=septal reduction therapy.
ADVERSE REACTIONS
Based on the safety profile from the pivotal EXPLORER-HCM trial, there were no new adverse reactions identified in VALOR-HCM.
This website is best viewed
using the horizontal display
on your tablet device.
This website is best viewed
using the vertical display
on your mobile device.
References: